The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
By cutting pain crises & boosting haemoglobin
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Revvity is positioning its technologies as a connected engine for discovery
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Subscribe To Our Newsletter & Stay Updated
